TAIHO PHARMA

We strive to
improve human
health and contribute
to a society enriched
by smiles

About Taiho

Becoming a truly global specialty pharma that meets the expectations of patients worldwide.

Our Business

Taiho Pharmaceutical creates innovative, highly valuable new drugs to support patients and the advancement of medicine, seeking to contribute to smiles and health for people all around the world.

News Releases

March 11, 2019

Taiho Pharmaceutical Announces Personnel Changes（PDF：126.9 KB）
February 26, 2019

FDA Approves LONSURF^® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
February 05, 2019

Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor（PDF：82.0 KB）
October 26, 2018

FDA Accepts Supplemental New Drug Application for LONSURF^® (trifluridine/tipiracil) for the Treatment of Metastatic Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma; Grants Priority Review
October 22, 2018

Taiho and Servier Announce Positive Results from LONSURF^® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology（PDF：100.5 KB）

Information

July 12, 2018

Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）